Patient Education and Support
Support and Quality of Life
Patient education is the cornerstone of effective management of dry eye syndrome (DES). It includes explaining the underlying disease processes and the chronic nature of the condition, the importance of consistent treatment, and the negative consequences of non-compliance, as well as providing clear instructions for the patient’s therapeutic regimens. Achieving patient understanding and compliance is paramount, as DES can progress into a more severe and treatment-resistant condition if not managed properly from the early stages. It is also crucial to periodically reassess the patient's compliance and understanding of the disease, the benefits of treatment, and potential complications. Patients considering surgical interventions, such as keratorefractive surgery, should be thoroughly educated on the potential risks, including the exacerbation of DES symptoms.
Dry eye syndrome imposes a considerable burden on patients, affecting their quality of life (QoL) and…
To continue reading
Log in or register to continue reading. It's free!
OR
By signing up to create an account, I accept Healio's Terms of Use and Privacy Policy.
Support and Quality of Life
Patient education is the cornerstone of effective management of dry eye syndrome (DES). It includes explaining the underlying disease processes and the chronic nature of the condition, the importance of consistent treatment, and the negative consequences of non-compliance, as well as providing clear instructions for the patient’s therapeutic regimens. Achieving patient understanding and compliance is paramount, as DES can progress into a more severe and treatment-resistant condition if not managed properly from the early stages. It is also crucial to periodically reassess the patient's compliance and understanding of the disease, the benefits of treatment, and potential complications. Patients considering surgical interventions, such as keratorefractive surgery, should be thoroughly educated on the potential risks, including the exacerbation of DES symptoms.
Dry eye syndrome imposes a considerable burden on patients, affecting their quality of life (QoL) and daily functioning. Supporting patients with DES involves addressing both the physical and emotional aspects of the condition. Support groups, such as the Sjögren’s Foundation (https://sjogrens.org), provide valuable resources and a sense of community, helping patients connect with others who face similar challenges.
These groups can offer practical advice, emotional support, and up-to-date information on managing DES. Additionally, professional counseling may be beneficial for some patients, aiding them in coping with the psychological stress associated with chronic conditions. Regular follow-up appointments with healthcare providers are essential to monitor disease progression, reassess treatment efficacy, and make necessary adjustments. By offering comprehensive support, including education, community resources, and professional counseling, healthcare providers can significantly enhance the overall well-being and QoL of patients with DES.
References
- Anwar Z, Wellik SR, Galor A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol. 2013;24(2):136-143.
- Aragona P, Giannaccare G, Mencucci R, Rubino P, Cantera E, Rolando M. Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol. 2021;105(4):446-453.
- Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45 Suppl 2:S211-S220.
- Choi SW, Kim J. Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review. Materials (Basel). 2018;11(7):1125.
- Dry Eye Syndrome PPP 2023. American Academy of Ophthalmology. Published February 13, 2024. https://www.aao.org/education/preferred-practice-pattern/dry-eye-syndrome-ppp-2023
- Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-349.
- Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628.
- Mantelli F, Tranchina L, Lambiase A, Bonini S. Ocular surface damage by ophthalmic compounds. Curr Opin Allergy Clin Immunol. 2011;11(5):464-470.
- Mondal H, Kim HJ, Mohanto N, Jee JP. A Review on Dry Eye Disease Treatment: Recent Progress, Diagnostics, and Future Perspectives. Pharmaceutics. 2023;15(3):990.
- Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther. 2001;18(5):205-215.
- Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423.
- Ramadan AA, Eladawy SA, El-Enin ASMA, et al. Development and investigation of timolol maleate niosomal formulations for the treatment of glaucoma. J Pharm Investig. 2020;50:59-70.
- Rolando M, Merayo-Lloves J. Management Strategies for Evaporative Dry Eye Disease and Future Perspective. Curr Eye Res. 2022;47(6):813-823.
- Rolando M, Vagge A. Safety and Efficacy of Cortisol Phosphate in Hyaluronic Acid Vehicle in the Treatment of Dry Eye in Sjogren Syndrome. J Ocul Pharmacol Ther. 2017;33(5):383-390.
- Rolando M, Zierhut M, Barabino S. Should We Reconsider the Classification of Patients with Dry Eye Disease?. Ocul Immunol Inflamm. 2021;29(3):521-523.
- Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. Ann Med. 2023;55(1):241-252.
- Singh RB, Ichhpujani P, Thakur S, Jindal S. Promising therapeutic drug delivery systems for glaucoma: a comprehensive review. Ther Adv Ophthalmol. 2020;12:2515841420905740.
- Stalmans I, Sunaric Mégevand G, Cordeiro MF, et al. Preservative-free treatment in glaucoma: who, when, and why. Eur J Ophthalmol. 2013;23(4):518-525.
- Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391-398.
- Verjee MA, Brissette AR, Starr CE. Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians. Ophthalmol Ther. 2020;9(4):877-888.
